US 6,642,039 B1 · 25312, a novel human agmatinase-like homolog

Abstract

The present invention relates to a newly identified human agmatinase-like arginase, designated “25312”. The invention also relates to polynucleotides encoding the agmatinase-like arginase. The invention further relates to methods using the agmatinase-like polypeptides and polynucleotides as a target for diagnosis and treatment in disorders mediated by or related to the agmatinase-like arginase. The invention further relates to drug-screening methods using the polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the polypeptides and polynucleotides. The invention further relates to agonists and antagonists identified by drug screening methods with the polypeptides and polynucleotides as a target.

Claims7

Dependent claims

An isolated polypeptide selected from the group consisting of:

a) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:
1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6, or the nucleotide sequence of the cDNA insert of the plasmid deposited with ATCC as Patent Deposit Number PTA-1844;
and
b) a polypeptide having at least 95% sequence identity to the amino acid sequence SEQ ID NO:2 or SEQ ID NO:4,
wherein the polypeptide has agmatinase activity.

2 more elements

Dependencies are inferred from the claim text.

25312, a novel human agmatinase-like homolog

Life of this patent

25312, a novel human agmatinase-like homolog

Life of this patent

Abstract

Claims7